Unresectable Undifferentiated Pleomorphic Sarcoma
5 clinical trials · Condition
◉ Watch Unresectable Undifferentiated Pleomorphic Sarcoma
| Record | Firm | Date |
|---|---|---|
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas (NCT06422806) | National Cancer Institute (NCI) | 2024-09-11 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (NCT05711615) | National Cancer Institute (NCI) | 2024-02-06 |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (NCT05836571) | National Cancer Institute LAO | 2023-10-25 |
| Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study (NCT05017103) | M.D. Anderson Cancer Center | 2021-07-13 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (NCT03009201) | OHSU Knight Cancer Institute | 2017-03-10 |
Track Unresectable Undifferentiated Pleomorphic Sarcoma automatically
Every clearance here is in the API, with alerts when new ones post.